10-K: Calidi Biotherapeutics Faces Going Concern Doubt Amidst Losses

Calidi Biotherapeutics reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing its RedTail platform and securing recent financings.

Summary

• Calidi Biotherapeutics is a publicly traded biotechnology company focused on developing targeted therapies using engineered oncolytic viruses and allogeneic stem cells for cancer treatment.
• The company has a limited operating history, has not generated any revenue from product sales to date, and has incurred significant operating losses since its inception, with a net loss of $20.1 million for the year ended December 31, 2025, and an accumulated deficit of $141.6 million.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the financial statement issuance date, necessitating additional capital raises.
• The RedTail platform, featuring an engineered enveloped oncolytic virus (CLD-401), is designed for systemic delivery to metastatic tumor sites, aiming to avoid immune clearance and deliver genetic medicines like IL-15 superagonist.
• An Investigational New Drug (IND) application for a Phase 1 trial of CLD-401 in metastatic solid tumors is expected to be filed by the end of 2026, with parallel efforts for a Phase 1 study in Australia.
• The legacy SuperNova (CLD-201) and NeuroNova (CLD-101) platforms use oncolytic viruses embedded in stem cells; CLD-201 received Fast Track Designation from the FDA in July 2025 for soft tissue sarcoma, and CLD-101 is in a Phase 1 trial funded by City of Hope for recurrent High Grade Glioma (HGG).
• The company raised approximately $4.3 million in gross proceeds from a Confidentially Marketed Public Offering (CMPO) in January 2025, $3.5 million from a Registered Direct Offering in March 2025, $4.6 million from a Warrant Inducement Offer in July 2025, and $6.9 million from a Public Offering in August 2025.
• In March 2026, the company completed another CMPO, raising approximately $6.0 million in gross proceeds, and amended certain outstanding warrants to reduce their exercise price to $0.50 per share.
• Two reverse stock splits were effected: 1-for-10 on July 15, 2024, and 1-for-12 on August 4, 2025, retrospectively adjusting all share and per-share amounts.
• The company sold its 75% ownership interest in Nova Cell, Inc. for $6.0 million in October 2025, satisfied partly by debt cancellation ($1.2 million) and deferred consideration ($4.8 million, currently constrained).
• Legal proceedings are ongoing involving former executives (Tony Kalajian and Hazel Sanchez) alleging defamation and constructive discharge, and a securities fraud complaint by Mr. Yian Zeng.
• The company's public warrants were delisted from the NYSE American in October 2024 due to low trading price and now trade on the OTC Pink Marketplace.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the explicit 'going concern' warning, significant accumulated losses, and the delisting of public warrants, which overshadow the clinical progress and recent capital raises. The need for continuous financing at potentially dilutive terms indicates ongoing financial instability.

Positives

• The RedTail platform represents a novel approach to cancer treatment with systemic delivery potential, designed to overcome immune clearance and target metastatic sites.
• CLD-401, the lead compound from the RedTail platform, demonstrated enhanced biological efficacy and complete tumor eradication in syngeneic animal models when combined with its genetic payload.
• CLD-201 (SuperNova) received Fast Track Designation from the FDA in July 2025 for soft tissue sarcoma, potentially accelerating its development and review process.
• The company has an open IND for a Phase 1 trial for SuperNova (CLD-201) and its NeuroNova (CLD-101) candidate is in a Phase 1 trial funded by City of Hope.
• Multiple equity financings in 2025 and early 2026, including CMPOs, a Registered Direct Offering, a Warrant Inducement Offer, and a Public Offering, collectively raised significant gross proceeds to support operations.
• The sale of the 75% ownership in Nova Cell, Inc. for $6.0 million provides a source of funds, including $1.2 million from debt cancellation.
• The company maintains a robust patent portfolio, with the newest patent family for RedTail technology providing protection until 2045 and possibly beyond.

Negatives

• The company has a limited operating history and has not generated any revenue from product sales to date.
• Significant operating losses have been incurred since inception, with a net loss of $20.1 million in 2025 and an accumulated deficit of $141.6 million.
• There is substantial doubt about the company's ability to continue as a going concern for the next 12 months due to insufficient cash ($5.6 million as of December 31, 2025) and ongoing operating losses.
• The company will need to raise substantial additional funding, which may lead to further dilution for existing shareholders and could be difficult to obtain on favorable terms.
• The trading price of common stock has decreased significantly, making it unlikely that the company will receive any settlement amount under the Forward Purchase Agreements.
• The public warrants were delisted from the NYSE American in October 2024 due to low trading price, impacting liquidity and market value.
• The novel nature of the product candidates (enveloped vaccinia virus and engineered allogeneic stem cells) creates significant development challenges and regulatory uncertainties.
• The company faces substantial competition from major pharmaceutical and biotechnology companies with greater financial resources and expertise.
• Ongoing legal proceedings with former executives and a securities fraud complaint could incur significant legal expenses and divert management attention.
• The deferred consideration of $4.8 million from the Nova Cell sale remains constrained until underlying uncertainties are resolved, limiting immediate cash access.

Risks

• Insufficient cash to continue operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Incurrence of significant operating losses since inception and anticipation of continued losses for the foreseeable future.
• No products approved for commercial sale and no revenue generated from product sales to date.
• The novel approach of enveloped vaccinia virus and engineered allogeneic stem cell product candidates creates significant development and regulatory challenges.
• Adverse publicity regarding stem cell-based immunotherapy could materially impact the business, including fundraising and personnel recruitment.
• Inability to raise substantial additional funding when needed could force delays, reductions, or elimination of product development programs or cessation of operations.
• High dependence on the success of RedTail product candidates; failure of CLD-401 could significantly harm development plans and the entire platform.
• Preclinical studies and clinical trials may fail to demonstrate adequate safety and efficacy, preventing or delaying development, regulatory approval, and commercialization.
• Interim, top-line, and preliminary data from clinical trials may change, and final data are subject to regulatory audit and verification procedures.
• Results of earlier studies and trials may not be predictive of future trial results, leading to potential setbacks in later stages.
• Lengthy, time-consuming, and unpredictable regulatory approval processes by the FDA and other authorities, potentially delaying or preventing commercialization.
• Breakthrough Therapy designation, if granted, may not lead to faster development or approval and does not guarantee marketing approval.
• Inability to file INDs or IND amendments on expected timelines, or regulatory authorities not permitting clinical trials to proceed.
• Potential competition from biosimilars for investigational products regulated as biologics, approved through an abbreviated regulatory pathway.
• Negative impact of healthcare legislative reform measures on business, financial condition, results of operations, and prospects.
• Potential product liability exposure from clinical trials and commercial sales, leading to substantial liability and commercialization limitations.
• Misconduct or improper activities by employees, independent contractors, consultants, commercial partners, principal investigators, or CROs, including noncompliance with regulatory standards and insider trading.
• Violations of or liabilities under environmental, health, and safety laws and regulations, leading to fines, penalties, or other costs.
• Dependence on banks insured by the FDIC to safeguard cash deposits; potential delays or loss of uninsured deposits if a bank enters receivership.
• Reliance on third parties (clinical investigators, CROs) to conduct clinical trials; failure to meet obligations could delay or impair regulatory approval.
• Rights to develop and commercialize product candidates are subject to third-party licenses; failure to comply with obligations could lead to loss of intellectual property rights.
• Potential for third parties to assert intellectual property infringement claims, leading to litigation, substantial damages, or injunctions.
• Inability to protect the confidentiality of trade secrets, harming business and competitive position.
• Volatility in stock price and potential difficulty in selling shares due to limited trading volume and broad market factors.
• Risk of delisting from the NYSE American if continued listing standards are not met, impacting market value and liquidity.
• Uncertainties and costs surrounding patent prosecution and enforcement due to changes in patent law.
• Inadequate patent terms to protect competitive position for a sufficient amount of time.
• Failure to obtain patent term extension and data exclusivity for product candidates.
• Inadequate protection of trademarks and trade names, hindering name recognition.
• Risks associated with expanding development, manufacturing, and regulatory capabilities, and implementing sales, marketing, and distribution capabilities.
• New risks and challenges from increasing use of social media, including liability, data security breaches, or reputational damage.
• Failure or security breaches of internal computer systems or those of third-party contractors, disrupting product development programs.
• Impact of natural disasters, pandemics, or other catastrophic events on operations.
• Increased scrutiny of Chinese biopharmaceutical industry potentially affecting contract manufacturing relationships.
• Inability to maintain an effective system of internal control over financial reporting, leading to inaccurate financial reports or fraud.

Future Outlook

Calidi Biotherapeutics expects to continue incurring significant operating losses as it advances its RedTail platform and other product candidates through preclinical and clinical development, seeks regulatory approvals, and potentially builds commercialization capabilities. The company anticipates filing an IND for a Phase 1 trial of CLD-401 by the end of 2026 and pursuing a parallel Phase 1 study in Australia. Future capital requirements are substantial, and the company will need to secure additional funding through equity or debt financings, or collaborations, to support its operations and growth strategy. The company also plans to continue cost-efficient manufacturing and opportunistically out-license its products.

Management Comments

• "We are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease."
• "Our RedTail platform is the culmination of over a decade of work around genetic engineering of viruses and allows for the systemic administration of a proprietarily-modified oncolytic virus."
• "We believe that RedTail, given its systemic administration and targeting to metastatic sites and its delivery of genetic medicines, represents a major advancement in the space of oncolytic virus in oncology."
• "We expect to file an investigational new drug (IND) application for a Phase I trial by the end of 2026 with CLD-401, the first compound from the RedTail platform, delivering IL-15 superagonist to the tumor microenvironment (TME)."
• "We expect to continue to incur significant and increasing operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company."
• "We have concluded that this circumstance raises substantial doubt about our ability to continue as a going concern."
• "Our ability to continue as a going concern is contingent upon, among other factors, the sale of our securities."

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics operates in the highly competitive and rapidly evolving immuno-oncology sector, specifically focusing on oncolytic viral immunotherapies. While the company's RedTail platform represents a novel approach to systemic delivery, addressing a key limitation of current oncolytic viruses like Amgen's T-VEC, it faces significant competition from major pharmaceutical and biotechnology companies such as AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche/Genentech, which possess substantially greater financial resources and R&D expertise. The industry is characterized by lengthy and expensive development cycles, high failure rates, and complex regulatory pathways, making Calidi's reliance on external funding and successful clinical outcomes critical. The delisting of public warrants and the low trading price of its common stock highlight the challenges smaller, early-stage biotech companies face in maintaining market confidence and securing capital amidst broader economic volatility and intense competition for investor funds.

Comparison to Industry Standards

• Calidi's RedTail platform aims to overcome a major obstacle in oncolytic virotherapy – rapid immune elimination – which has limited the success of existing therapies like Amgen's T-VEC (Imlygic) to local delivery. If successful, RedTail's systemic delivery could represent a significant advancement over current standards for metastatic disease.
• The Fast Track Designation for CLD-201 for soft tissue sarcoma indicates potential to address an unmet medical need, aligning with regulatory efforts to expedite development for serious conditions, similar to other innovative therapies in the oncology space.
• The company's reliance on third-party CDMOs for manufacturing is a common industry practice for early-stage biotechs, but the lack of long-term supply arrangements and the complexity of enveloped virus production pose risks compared to larger pharmaceutical companies with in-house, established GMP facilities.
• The substantial accumulated deficit and going concern warning are typical for early-stage biotechnology companies that are pre-revenue and heavily invested in R&D, but the frequency and size of recent capital raises indicate a high burn rate relative to its market capitalization and current stage of development, which is a concern for investors compared to more financially stable industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• Tony Kalajian, former Chief Accounting Officer and interim Chief Financial Officer, filed a complaint in November 2023 alleging defamation and constructive discharge, seeking unspecified damages and attorneys' fees. The company initiated arbitration against Mr. Kalajian for breach of fiduciary duty and constructive fraud, seeking to recover unauthorized bonuses.
• Hazel Sanchez, former Controller, filed a complaint in November 2023 alleging defamation, constructive discharge, California Family Rights Act violation, and wrongful discharge, seeking unspecified damages and attorneys' fees. The company filed a Cross-Complaint against Ms. Sanchez for breach of fiduciary duty and constructive fraud, seeking to recover unauthorized bonuses.
• Mr. Kalajian filed a Petition for Writ of Mandate in February 2024 to compel production of corporate records, which was voluntarily dismissed in March 2025.
• Mr. Kalajian filed a complaint in May 2024 alleging intentional conversion and violation of Delaware General Corporations Code due to failure to remove a restrictive legend from 1,162 shares of common stock, seeking compensatory and punitive damages, and attorneys' fees.
• The Primary Case, Kalajian Arbitration, Sanchez Case, and Conversion Case have been consolidated, with a trial date set for November 6, 2026.
• In July 2025, the company filed a lawsuit against a former executive assistant alleging breach of fiduciary duty, constructive fraud, conversion, and misappropriation of confidential information, seeking injunctive relief and damages. The outcome is uncertain, but management does not expect a material adverse effect.
• Mr. Yian Zeng filed a complaint on October 29, 2024, alleging securities fraud, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive fraud. The company denies all claims and is vigorously opposing the case. Mandatory settlement conferences in April 2025 and January 2026 resulted in no resolution. A final pre-trial conference is set for October 19, 2026, with no trial date yet set.

Related Party Transactions

• As of December 31, 2024, $2.7 million in related party term notes payable were due to Directors A and E, which were settled in full in January 2025.
• Amounts owed to Director F (Allan J. Camaisa) and a relative of Officer A for reimbursable expenses and legal fees, totaling $30 thousand as of December 31, 2024.
• Severance accrual of $195 thousand for Director F (Allan J. Camaisa) as of December 31, 2025, related to his separation pay and transition/consulting pay.
• Severance accrual of $434 thousand for Director D (George K. Ng) as of December 31, 2024, which was settled in full in January 2025.
• Advisory services fees of $18 thousand owed to Director A (Scott Leftwich) as of December 31, 2024, which were settled in January 2025.
• A lease guaranty of up to $0.9 million provided by Director F (Allan J. Camaisa) for the San Diego Lease, with the company obligated to pay him 10% of the guaranty amount for the first year and 5% per annum thereafter. $0.2 million was received by Mr. Camaisa in 2025 in connection with this.
• Other liabilities of $638 thousand to Director A (Scott Leftwich) as of December 31, 2024, for deferred compensation and advisory fees, settled in January 2025.
• Warrant liabilities of $8 thousand to Director F and Director A as of December 31, 2025, and $9 thousand as of December 31, 2024.
• A loan payable of $0.2 million to a relative of Officer A in January 2024, bearing 12% interest, settled in full in January 2025.
• Severance accrual of $65 thousand for Officer G (Dr. Boris Minev) as of December 31, 2025, including a bonus and severance pay.
• Severance accrual of $158 thousand for Officer A (Ms. Wendy Pizarro Campbell) as of December 31, 2025, including a bonus and severance pay.
• Accrued $130 thousand due to Company A, related to Director G, for contract research organization (CRO) services as of December 31, 2025. Incurred $0.6 million in expenses for these services in 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing and future equity financings due to the company's substantial capital needs and low stock price. The 'going concern' warning and delisting of public warrants indicate high investment risk and potential for further share price volatility and decline. Existing shareholders who purchased at higher prices may not realize similar profits as early investors.
• **Employees:** The company's financial instability and need for continuous funding create uncertainty regarding job security and long-term compensation. Changes in executive positions and the elimination of roles may impact morale and organizational stability. Equity incentive plans are in place to attract and retain talent, but their value is tied to stock performance.
• **Customers (future):** The success of product candidates and their eventual commercialization depends on regulatory approvals and market acceptance. Delays or failures in clinical trials could impact the availability of new therapies for patients.
• **Suppliers/Creditors:** The 'going concern' warning and reliance on additional funding may raise concerns among suppliers and creditors regarding the company's ability to meet its contractual obligations, potentially affecting terms or availability of services/credit.
• **Regulatory Authorities:** The company's novel therapeutic approaches and ongoing clinical trials require close scrutiny and compliance with stringent regulations. Any non-compliance or adverse events could lead to regulatory actions, impacting development timelines and approvals.

Next Steps

• File an Investigational New Drug (IND) application for a Phase 1 trial of CLD-401 in patients with metastatic solid tumors by the end of 2026.
• Initiate a Phase 1 study in Australia for CLD-401 in parallel.
• Continue to advance the enveloped oncolytic virotherapy (RedTail) platform.
• Explore combination therapy studies using the RedTail platform with other immunotherapies.
• Continue to pursue cost-efficient manufacturing processes for enveloped viruses.
• Opportunistically pursue out-licensing of enveloped virus and stem cell derived products, anticipating one or more distribution relationships.
• Raise additional capital through public or private equity/debt financings or collaboration agreements to support continuing operations and growth strategy.
• Continue to invest in internal development capabilities to establish critical in-house manufacturing expertise.
• Evaluate whether to establish own CGMP manufacturing facilities for commercial production.

Key Dates

Recommendation

The filing presents a dire financial situation, explicitly stating 'substantial doubt about the Company’s ability to continue as a going concern' due to recurring losses and insufficient cash. While clinical progress is noted, the company is pre-revenue and heavily reliant on highly dilutive equity financings, as evidenced by multiple offerings and warrant amendments reducing exercise prices. The delisting of public warrants from NYSE American further underscores severe market perception issues. The current trading price is significantly below the initial reset price for Forward Purchase Agreements, indicating a high likelihood of no settlement funds from these derivatives. These factors collectively point to extreme financial risk and a high probability of further value erosion for shareholders.

Keywords

Biotechnology, Oncolytic Virus, Cancer Therapy, RedTail Platform, CLD-401, SuperNova, CLD-201, NeuroNova, CLD-101, Metastatic Solid Tumors, High Grade Glioma, Soft Tissue Sarcoma, Stem Cell Therapy, Genetic Medicines, FDA Fast Track, Clinical Trials, SEC Filing, Going Concern, Equity Financing, Warrants, Reverse Stock Split, Intellectual Property, Regulatory Approval, Biopharmaceutical